Team:LCG-UNAM-Mexico/Notebook/2008-June 2
From 2008.igem.org
(7 intermediate revisions not shown) | |||
Line 75: | Line 75: | ||
<tr> | <tr> | ||
<td width="224" valign="top" bgcolor="#5C743D"> | <td width="224" valign="top" bgcolor="#5C743D"> | ||
- | + | <table border="0" cellspacing="0" cellpadding="0" width="165" id="navigation"> | |
<tr> | <tr> | ||
<td width="165" bgcolor="#5C743D"> <br /> | <td width="165" bgcolor="#5C743D"> <br /> | ||
Line 84: | Line 84: | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
- | <td width="165" bgcolor="#5C743D"><a href="https://2008.igem.org/Team:LCG-UNAM-Mexico/ | + | <td width="165" bgcolor="#5C743D"><a href="https://2008.igem.org/Team:LCG-UNAM-Mexico/Project" class="navText">Our project</a></td> |
</tr> | </tr> | ||
<tr> | <tr> | ||
- | <td width="165" bgcolor="#5C743D"><a href="https://2008.igem.org/Team:LCG-UNAM-Mexico/ | + | <td width="165" bgcolor="#5C743D"><a href="https://2008.igem.org/Team:LCG-UNAM-Mexico/Modeling" class="navText">Modeling</a></td> |
</tr> | </tr> | ||
<tr> | <tr> | ||
- | <td width="165" bgcolor="#5C743D"><a href="https://2008.igem.org/Team:LCG-UNAM-Mexico/Experiments" class="navText"> | + | <td width="165" bgcolor="#5C743D"><a href="https://2008.igem.org/Team:LCG-UNAM-Mexico/Experiments" class="navText">Wet Lab</a></td> |
</tr> | </tr> | ||
<tr> | <tr> | ||
Line 96: | Line 96: | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
- | <td width="165" bgcolor="#5C743D"><a href="https://2008.igem.org/Team:LCG-UNAM-Mexico/ | + | <td width="165" bgcolor="#5C743D"><a href="https://2008.igem.org/Team:LCG-UNAM-Mexico/Notebook" class="navText">Notebook</a></td> |
</tr> | </tr> | ||
<tr> | <tr> | ||
- | <td width="165" bgcolor="#5C743D"><a href="https://2008.igem.org/Team:LCG-UNAM-Mexico/ | + | <td width="165" bgcolor="#5C743D"><a href="https://2008.igem.org/Team:LCG-UNAM-Mexico/Story" class="navText">Our story</a></td> |
+ | </tr> | ||
+ | <tr> | ||
+ | <td width="165" bgcolor="#5C743D"><a href="https://2008.igem.org/Team:LCG-UNAM-Mexico/Team" class="navText">About us</a></td> | ||
</tr> | </tr> | ||
- | + | ||
- | + | </table> <br /> | |
<br /> | <br /> | ||
<br /> | <br /> | ||
Line 121: | Line 124: | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
- | <td class="bodyText"><p><strong>Final design</strong></p> | + | <td class="bodyText"><div align="justify"><p><strong><u>Final design</u></strong></p> |
<p>Scheme</p> | <p>Scheme</p> | ||
<p><div id="pbfw"> | <p><div id="pbfw"> | ||
Line 127: | Line 130: | ||
</div> | </div> | ||
<p align="center"><br /></p> | <p align="center"><br /></p> | ||
- | <p>The first plasmid contains the efflux pump for Nickel ( | + | <p>The first plasmid contains the efflux pump for Nickel (RcnA), which will maintain its natural regulation dependent of RcnR and additionally, it will contain a promoter regulated by the repressor of lambda phage, cI as well as a resistance as a marker of the plasmid. </p> |
<p> | <p> | ||
- | The second contains everything needed for regulating | + | The second plasmid contains everything needed for regulating RcnA dependent on an external signal (AHL). Both luxR and aiiA will be synthesised constitutively. LuxR with a strong promoter (pTetR), as we do not want the presence of LuxR to be limiting and aiiA under the control of a moderate or weak promoter (pLacZ) for it is a very efficient enzyme, and we don't want it to degrade all AHL and prevent the signal from being transmitted. And cI*, which is a version of cI tagged with an LVA tail for rapid degradation, regulated by a promoter dependent of LuxR + AHL. It will also contain a resistance as a marker. </p> |
<p> | <p> | ||
- | + | When AHL is added, it will bind LuxR and stimulate the production of cI*, which in turn will represses the transcription of rcnA. Like cI*, the signal produced by AHL will be short-lived since aiiA will be degradating it constantly, so the system quickly returns to its initial state. <br /> | |
<br /> | <br /> | ||
<strong>Parts </strong><br /> | <strong>Parts </strong><br /> | ||
- | |||
Defining bioparts we will use or where to get what is necessary. <br /> | Defining bioparts we will use or where to get what is necessary. <br /> | ||
- | + | <br /> | |
- | <strong>Part: BBa_I729006</strong></ | + | <li><strong><i>Part: BBa_I729006</strong></i></li></p> |
<p><div id="pbfw"> | <p><div id="pbfw"> | ||
<div id="ub_r"> | <div id="ub_r"> | ||
Line 143: | Line 145: | ||
</div> | </div> | ||
</div> | </div> | ||
- | <p align="center" | + | <p align="center"></p> |
<p>Part of Quorum sensing used by the team Chiba in iGEM2007. Both tetR and LacI + pL are constitutive promoters, but since LacI + pL is a very strong promoter, it will probably be replaced. This biopart will be responsible for the regulation by luxR and the action of the system by AHL. Instead of GFP (Subpart E0040), the BBa_C0051 part that codes for the protein cI + LVA will be inserted, which will join the regulatory region of cI (biopart BBa_R0051) in the other plasmid.</p> | <p>Part of Quorum sensing used by the team Chiba in iGEM2007. Both tetR and LacI + pL are constitutive promoters, but since LacI + pL is a very strong promoter, it will probably be replaced. This biopart will be responsible for the regulation by luxR and the action of the system by AHL. Instead of GFP (Subpart E0040), the BBa_C0051 part that codes for the protein cI + LVA will be inserted, which will join the regulatory region of cI (biopart BBa_R0051) in the other plasmid.</p> | ||
- | <p>(Previous experience: none)</p> | + | <p>(Previous experience: none)</p><br> |
- | <p><strong><em>Part:BBa_C0051</em></strong></p> | + | <p><li><strong><em>Part:BBa_C0051</em></strong></li></p> |
<p><div id="pbfw"> | <p><div id="pbfw"> | ||
<div id="ub_r"> | <div id="ub_r"> | ||
Line 154: | Line 156: | ||
</div> | </div> | ||
</div> | </div> | ||
- | <p align="center" | + | <p align="center"></p> |
- | <p>Region coding for the repressor cI | + | <p>Region coding for the repressor cI, of lambda phage, tagged with an LVA tail for rapid degradation. cI joins the regulator cI (BBa_R0051)</p> |
- | <p>(Previous experience: none)</p> | + | <p>(Previous experience: none)</p><br> |
- | <p><strong><em>Part:BBa_R0051</em></strong></p> | + | <p><li><strong><em>Part:BBa_R0051</em></strong></li></p> |
<p><div id="dmii"><img src="http://docs.google.com/File?id=dc5zwbn5_7fsbr26rq_b" alt="" width="580" id="zrt-" /></div> | <p><div id="dmii"><img src="http://docs.google.com/File?id=dc5zwbn5_7fsbr26rq_b" alt="" width="580" id="zrt-" /></div> | ||
- | <p align="center"> | + | <p align="center"> |
</p> | </p> | ||
- | <p>Promoter regulated by cI based on the pR promoter of lambda phage. The promoter has two binding sites | + | <p>Promoter regulated by cI based on the pR promoter of lambda phage. The promoter has two binding sites for the cI repressor of lambda phage (BBa_C0051). The binding of cI leads to the suppression of the transcript synthesis. </p> |
<p>(Previous experience: it works) <br /> | <p>(Previous experience: it works) <br /> | ||
<br /> | <br /> | ||
- | + | The sequence of the 3 previously mentioned bioparts is in the <a href = http://partsregistry.org/Main_Page> Registry of Standard Biological Parts </a> and according to the information provided by the registry, DNA is available. </p><br> | |
- | <p><strong><em> | + | <p><strong><em> <li> Part: BBa_G00510 </li></em></strong></p> |
- | <p> This is the forward primer | + | gatttctgcatagccagacttggg<br> |
- | + | <p> This is the forward primer for C0051, 24 bp long. <br /></p><br> | |
- | + | <p><strong><em> <li>Part: BBa_G00511 </li></em></strong></p> | |
- | <p><strong><em> Part: BBa_G00511 </em></strong></p> | + | cactgactagcgataactttccccac<br> |
- | <p> Reverse primer for C0051 | + | <p> Reverse primer for C0051, 26 bp long. <br /></p><br> |
- | + | ||
- | + | ||
<p><strong>Vectors</strong></p> | <p><strong>Vectors</strong></p> | ||
- | + | <p> Possibilities in bioparts: <br /> | |
- | <p> Possibilities | + | |
- | + | ||
- | + | ||
- | + | ||
<table width="500" border="2"> | <table width="500" border="2"> | ||
<tr> | <tr> | ||
Line 216: | Line 212: | ||
<td>pCK01BB1</td> | <td>pCK01BB1</td> | ||
</tr> | </tr> | ||
- | </table> | + | </table><br> |
<p><strong>Primers</strong></p> | <p><strong>Primers</strong></p> | ||
<p> Build or find oligos that we could use for our constructions.</p> | <p> Build or find oligos that we could use for our constructions.</p> | ||
<p> We need: <br /> | <p> We need: <br /> | ||
• rcnA (with its regulatory region; no promoter).<br /> | • rcnA (with its regulatory region; no promoter).<br /> | ||
- | • cI *.<br /> | + | • cI* with its AHL-LuxR dependent promoter.<br /> |
- | • | + | • LuxR with its constitutive tetR promoter. <br /> |
- | • | + | • AiiA with its constitutive promoter (lac is proposed, it is a moderate promoter).<br /> |
- | + | ||
• Promoter dependent of cI.<br /> | • Promoter dependent of cI.<br /> | ||
- | + | <span class="font-size: small"> In all cases, we have to check whether they already exist (in bioparts or elsewhere) and evaluate them. </span></p> | |
<table border="2" cellspacing="0" cellpadding="0" width="500"> | <table border="2" cellspacing="0" cellpadding="0" width="500"> | ||
<tr> | <tr> | ||
Line 234: | Line 229: | ||
<td width="94" valign="bottom"><p align="center"><strong>Tm</strong></p></td> | <td width="94" valign="bottom"><p align="center"><strong>Tm</strong></p></td> | ||
<td width="35" valign="bottom"><p align="center"><strong>Deg.</strong></p></td> | <td width="35" valign="bottom"><p align="center"><strong>Deg.</strong></p></td> | ||
- | <td width="67" valign="bottom"><p align="center"><strong>Restr. | + | <td width="67" valign="bottom"><p align="center"><strong>Restr. Site</strong></p></td> |
<td width="100" valign="bottom"><p align="center"><strong>Bioparts</strong></p></td> | <td width="100" valign="bottom"><p align="center"><strong>Bioparts</strong></p></td> | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
- | <td width="107" valign="bottom"><div> | + | <td width="107" rowspan="2 valign="bottom"><div> |
- | <p align="center">(pTetR)luxR/(p. </p> | + | <p align="center">(pTetR)luxR/(p.c.strong)aiiA </p> |
</div></td> | </div></td> | ||
<td width="56" valign="bottom"><div> | <td width="56" valign="bottom"><div> | ||
Line 261: | Line 256: | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
- | |||
- | |||
- | |||
<td width="56" valign="bottom"><div> | <td width="56" valign="bottom"><div> | ||
<p align="center">Lower </p> | <p align="center">Lower </p> | ||
Line 444: | Line 436: | ||
</tr> | </tr> | ||
</table> | </table> | ||
+ | <br> | ||
<p><strong>Promoters</strong></p> | <p><strong>Promoters</strong></p> | ||
- | <p>Investigate | + | <p>Investigate more about the proposed promoters and define if they are the most optimal depending on our needs.</p> |
<table border="2" cellspacing="0" cellpadding="0" width="580"> | <table border="2" cellspacing="0" cellpadding="0" width="580"> | ||
<tr> | <tr> | ||
Line 615: | Line 608: | ||
</tr> | </tr> | ||
</table> | </table> | ||
+ | <br> | ||
<p><strong>Facts about kinetics & other things...</strong></p> | <p><strong>Facts about kinetics & other things...</strong></p> | ||
<p> | <p> | ||
- | Investigate | + | Investigate more about the elements of the system to begin building an outline for the model and defining if design is theoretically feasible. <br /> |
<br /> | <br /> | ||
- | + | NOTES: For LuxR to bind HSL and enable the transcription of cI, HLS should be at a micromolar concentration.<br /> | |
- | + | Not all bioparts have been previously used, most DNA is available but there is still no record their functionality. We need to evaluate the DNA quality to ensure that there will be no problems.</p></div> | |
</tr> | </tr> | ||
<tr> | <tr> | ||
Line 626: | Line 620: | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
- | <td class="bodyText">< | + | <td class="bodyText"><div align="justify"><p><strong><u>MODELING:</u></strong><br> |
<strong id="j4px695"><img src="http://docs.google.com/File?id=dntmktb_59hmv4brc3_b" alt="" name="graphics3" width="255" height="289" hspace="13" border="0" align="left" id="j4px696" /></strong><br><strong>Variables</strong> <br> | <strong id="j4px695"><img src="http://docs.google.com/File?id=dntmktb_59hmv4brc3_b" alt="" name="graphics3" width="255" height="289" hspace="13" border="0" align="left" id="j4px696" /></strong><br><strong>Variables</strong> <br> | ||
Concentrations of:</p> | Concentrations of:</p> | ||
- | |||
<li>LuxR (constant). </li> | <li>LuxR (constant). </li> | ||
<li>aiiA (constant). </li> | <li>aiiA (constant). </li> | ||
Line 635: | Line 628: | ||
<li>cI* (according to aiiA, AHL & LuxR). </li> | <li>cI* (according to aiiA, AHL & LuxR). </li> | ||
<li>RcnA (according to cI*). </li> | <li>RcnA (according to cI*). </li> | ||
- | + | <p>We need to determine the initial concentrations and lifetime of proteins involved, as well as the efficiency of AiiA (kinetics in general). <br /> | |
- | <p> | + | The concentration of Nickel (NiCl2) in the medium that the cells can tolerate according to Rodrigue et al. (2005) before inhibiting growth is 4 μ M for the strain lacking rcnA, 10 μM in the wildtype and up to 100-fold more in a strain with a multicopy gene.</p><br /> |
- | + | ||
<p> </p> | <p> </p> | ||
<table border="0" cellspacing="0" cellpadding="0"> | <table border="0" cellspacing="0" cellpadding="0"> | ||
Line 687: | Line 679: | ||
</tr> | </tr> | ||
</table> | </table> | ||
- | <p><em>Assumption 1:</em> Once there is nickel in the medium, RcnR | + | <p><em>Assumption 1:</em> Once there is nickel in the medium, RcnR will not interfere in the pump regulation. This because there will be large concentrations of metal, so we can assume that RcnR will always be bound to a molecule of nickel and it will therefore be unable to suppress the transcription of rcnA; the noise that the few RcnR free molecules can cause, will be indistinguishable from normal behaviour of the pump. <br /> |
</p> | </p> | ||
- | <p><em>Assumption 2:</em> Any decrease in the concentration of AHL is due to aiiA. It is believed that the natural degradation of this is irrelevant in the time scale analysis. Either way, a process will not be distinguishable from the other and even when the first is estimated, it would not be very informative for the analysis, so we intend to take this assumption as true. <br /> | + | <p><em>Assumption 2:</em> Any decrease in the concentration of AHL is due to aiiA. It is believed that the natural degradation of this molecule is irrelevant in the time scale analysis. Either way, a process will not be distinguishable from the other and even when the first is estimated, it would not be very informative for the analysis, so we intend to take this assumption as true. <br /> |
</p> | </p> | ||
- | <p><em>Assumption 3:</em> The transcription of cI * depends solely on the | + | <p><em>Assumption 3:</em> The transcription of cI* depends solely on the concentration of AHL. LuxR is not a limiting step, ie, it is in a constant concentration and in sufficient amount to always be ready to associate with AHL. Only to simplify the analysis, at least for our first approach.</p> |
<p><strong>Initial outline:</strong></p> | <p><strong>Initial outline:</strong></p> | ||
<p>(v1) AHL0 <br /> | <p>(v1) AHL0 <br /> | ||
Line 701: | Line 693: | ||
RcnA -> Ø </p> | RcnA -> Ø </p> | ||
<p align="center"> </p> | <p align="center"> </p> | ||
- | </td> | + | </div></td> |
</tr> | </tr> | ||
<tr> | <tr> | ||
Line 707: | Line 699: | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
- | <td class="bodyText"><p><p><strong> | + | <td class="bodyText"><div align="justify"><p><p><strong><u>WET LAB:</u></strong></p> |
- | < | + | |
<p>1. Take the sequences (fasta format) <br /> | <p>1. Take the sequences (fasta format) <br /> | ||
2. Once you have the sequence find appropriate reading frames <br /> | 2. Once you have the sequence find appropriate reading frames <br /> | ||
Line 716: | Line 707: | ||
We have to take the whole sequence in fasta format and use it in a program called Gene Construction Kit. This shows reading frames and restriction sites. </p> | We have to take the whole sequence in fasta format and use it in a program called Gene Construction Kit. This shows reading frames and restriction sites. </p> | ||
<p> </p> | <p> </p> | ||
- | <p>In fruitfly.org: 9005/seq_tools/promoter.html we can look for primers and we can adjust parameters. We can also analyze the stability energy, and seek the lowest point of stability. This point is generally the -10box. To find inverted repeats, we shall use the program StemLoop of the parcel of GCG (genetics computer group). This program calls in the sequence in a GCG format. To find direct repeats we will use the program "repeat". For rcnR and rcnA we found three direct repeats between the -10 box and the translation start of rcnA.We suggest that this is a regulatory region. Based on this, we designed the primers, trying to preserve the regulatory region and changing its promoter.</p> | + | <p>In <a href= http://fruitfly.org:9005/seq_tools/promoter.html> fruitfly.org: 9005/seq_tools/promoter.html </a>we can look for primers and we can adjust parameters. We can also analyze the stability energy, and seek the lowest point of stability. This point is generally the -10box. To find inverted repeats, we shall use the program StemLoop of the parcel of GCG (genetics computer group). This program calls in the sequence in a GCG format. To find direct repeats we will use the program "repeat". For rcnR and rcnA we found three direct repeats between the -10 box and the translation start of rcnA.We suggest that this is a regulatory region. Based on this, we designed the primers, trying to preserve the regulatory region and changing its promoter.</p> |
<p> </p> | <p> </p> | ||
- | <p><em>Primer design.</em> The region should be rich in GC, of about 20 nucleotides with a 50% GC content at least and it should finish in G. The program can also show the double chain to facilitate the design of oligo lower. If they are rich in AT, they can be longer primers to increase its Tm. </p> | + | <p><em><b>Primer design.</b></em><br> The region should be rich in GC, of about 20 nucleotides with a 50% GC content at least and it should finish in G. The program can also show the double chain to facilitate the design of oligo lower. If they are rich in AT, they can be longer primers to increase its Tm. </p> |
<p> </p> | <p> </p> | ||
<p>The most popular program at the center is Oligo. Here we open a new window and paste the sequence. This will open two windows. The first one with the Tm, and the other one with the free energy. The program can calculate all oligos and show potential couples with its parameters. We can also specify were we want the oligo to be located. Once the program generates it, we can analyze its biochemical properties. </p> | <p>The most popular program at the center is Oligo. Here we open a new window and paste the sequence. This will open two windows. The first one with the Tm, and the other one with the free energy. The program can calculate all oligos and show potential couples with its parameters. We can also specify were we want the oligo to be located. Once the program generates it, we can analyze its biochemical properties. </p> | ||
Line 732: | Line 723: | ||
<p>The contents of the tube will be put in an eppendorf, we centrifuge and then we withdraw the liquid medium with a syringe. Before we lyse de cells, we need to wash with TE 10 1 (Tris 10uM EDTA 1uM), with pH 8. Vortex, to separate and disintegrate. Again, we centrifuge and remove supernatant. To lyse, we add 400-450 ul TE5020pH8 and SDS 10% and K proteinase. We leave it at 37 degrees for 20 minutes. The medium goes from an opaque color to a light color when lysis happens. We add ethanol 100% once we have lysed the cells and we vortex. In the presence of ethanol DNA is precipitated, so we add 1ml of ethanol. Then we centrifuge for a few minutes and we have pellet. We wash three times with ethanol 70%, which solubilised salts and the small molecules (including RNA). We remove all the ethanol, this tube is placed in a specific centrifuge. The vacuum from this centrifuge will remove the remain solvent. It is necessary to remove all the ethanol, because this affects the pH. TE 10 1 RNAs 10mg per ml, this Stock solution is divided 1000 times and 50ul approx are added. To check the quality of the DNA extracted, we use an agarose gel.</p> | <p>The contents of the tube will be put in an eppendorf, we centrifuge and then we withdraw the liquid medium with a syringe. Before we lyse de cells, we need to wash with TE 10 1 (Tris 10uM EDTA 1uM), with pH 8. Vortex, to separate and disintegrate. Again, we centrifuge and remove supernatant. To lyse, we add 400-450 ul TE5020pH8 and SDS 10% and K proteinase. We leave it at 37 degrees for 20 minutes. The medium goes from an opaque color to a light color when lysis happens. We add ethanol 100% once we have lysed the cells and we vortex. In the presence of ethanol DNA is precipitated, so we add 1ml of ethanol. Then we centrifuge for a few minutes and we have pellet. We wash three times with ethanol 70%, which solubilised salts and the small molecules (including RNA). We remove all the ethanol, this tube is placed in a specific centrifuge. The vacuum from this centrifuge will remove the remain solvent. It is necessary to remove all the ethanol, because this affects the pH. TE 10 1 RNAs 10mg per ml, this Stock solution is divided 1000 times and 50ul approx are added. To check the quality of the DNA extracted, we use an agarose gel.</p> | ||
<p> </p> | <p> </p> | ||
- | <p><em>Transforming bioparts: </em>Bacteria needed to extract DNA plasmid. Centrifuge, wash and put solution 1. Glucose, TRIS, EDTA and sometimes RNAs 1. Sodium hydroxide and SDS in the solution 2, sodium hydroxide denatures the DNA. Solution 3 with sodium acetate neutralizes the base. Wash and dry every time.</p></p> | + | <p><em><b>Transforming bioparts:</b> </em><br>Bacteria needed to extract DNA plasmid. Centrifuge, wash and put solution 1. Glucose, TRIS, EDTA and sometimes RNAs 1. Sodium hydroxide and SDS in the solution 2, sodium hydroxide denatures the DNA. Solution 3 with sodium acetate neutralizes the base. Wash and dry every time.</p></p> |
- | </td> | + | </div></td> |
</tr> | </tr> | ||
<tr> | <tr> |
Latest revision as of 01:12, 29 October 2008
LCG-UNAM-Mexico | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
iGEM 2008 TEAM | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||